MICS and phaco on a par?

Article

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss.

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss, according to a study published in the November/December 2006 issue of the European Journal of Ophthalmology.

Michal Wilczynski and colleagues from the Medical University of Lodz, Poland prospectively compared 40 eyes of 40 patients undergoing surgery. Half of the subjects underwent MICS and the other half underwent standard phaco with implantation of a foldable intraocular lens (IOL).

At ten days follow-up, the two groups had statistically similar mean best corrected visual acuity (BCVA); 0.94 in the MICS group and 0.9 in the phaco group (p>0.05). Both groups showed significant decreases in postoperative endothelial cell density and the losses were also statistically similar. The MICS patients lost an average of 9.5% of cells for a mean postoperative cell density of 2,235 cells/mm2. Patients in the phaco group lost an average of 7.6% of cells for a mean postoperative cell density of 2,079 cells/mm2 (p>0.05).

The authors of the study concluded that MICS and phacoemulsification result in statistically similar early endothelial cell losses, in addition to similar visual outcomes.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.